Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 235 entries
Sorted by: Best Match Show Resources per page
Emerging role of mTOR in the response to cancer therapeutics.

Trends in cancer

Ilagan E, Manning BD.
PMID: 27668290
Trends Cancer. 2016 May;2(5):241-251. doi: 10.1016/j.trecan.2016.03.008.

The movement toward precision medicine with targeted therapeutics for cancer treatment has been hindered by both innate and acquired resistance. Understanding the molecular wiring and plasticity of oncogenic signaling networks is essential to the development of therapeutic strategies to...

Cite
Ilagan E, Manning BD. Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer. 2016;2(5):241-251doi: 10.1016/j.trecan.2016.03.008.
Ilagan, E., & Manning, B. D. (2016). Emerging role of mTOR in the response to cancer therapeutics. Trends in cancer, 2(5), 241-251. https://doi.org/10.1016/j.trecan.2016.03.008
Ilagan, Erika, and Manning, Brendan D. "Emerging role of mTOR in the response to cancer therapeutics." Trends in cancer vol. 2,5 (2016): 241-251. doi: https://doi.org/10.1016/j.trecan.2016.03.008
Ilagan E, Manning BD. Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer. 2016 May;2(5):241-251. doi: 10.1016/j.trecan.2016.03.008. PMID: 27668290; PMCID: PMC5033243.
Copy Download .nbib Format: NLM
Long noncoding RNAs in cancer: from function to translation.

Trends in cancer

Sahu A, Singhal U, Chinnaiyan AM.
PMID: 26693181
Trends Cancer. 2015 Oct 01;1(2):93-109. doi: 10.1016/j.trecan.2015.08.010.

While our understanding of the molecular mechanisms underlying cancer has significantly improved, most of our knowledge focuses on protein-coding genes that make up a fraction of the genome. Recent studies have uncovered thousands of long noncoding RNAs (lncRNAs) that...

Cite
Sahu A, Singhal U, Chinnaiyan AM. Long noncoding RNAs in cancer: from function to translation. Trends Cancer. 2015;1(2):93-109doi: 10.1016/j.trecan.2015.08.010.
Sahu, A., Singhal, U., & Chinnaiyan, A. M. (2015). Long noncoding RNAs in cancer: from function to translation. Trends in cancer, 1(2), 93-109. https://doi.org/10.1016/j.trecan.2015.08.010
Sahu, Anirban, et al. "Long noncoding RNAs in cancer: from function to translation." Trends in cancer vol. 1,2 (2015): 93-109. doi: https://doi.org/10.1016/j.trecan.2015.08.010
Sahu A, Singhal U, Chinnaiyan AM. Long noncoding RNAs in cancer: from function to translation. Trends Cancer. 2015 Oct 01;1(2):93-109. doi: 10.1016/j.trecan.2015.08.010. PMID: 26693181; PMCID: PMC4672369.
Copy Download .nbib Format: NLM
Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020.

Frontiers in public health

Jakovljevic M, Malmose-Stapelfeldt C, Milovanovic O, Rancic N, Bokonjic D.
PMID: 28289676
Front Public Health. 2017 Feb 27;5:23. doi: 10.3389/fpubh.2017.00023. eCollection 2017.

BACKGROUND: Disability either due to illness, aging, or both causes remains an essential contributor shaping European labor markets. Ability of modern day welfare states to compensate an impaired work ability and absenteeism arising from incapacity is very diverse. The...

Cite
Jakovljevic M, Malmose-Stapelfeldt C, Milovanovic O, et al. Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020. Front Public Health. 2017;5:23doi: 10.3389/fpubh.2017.00023.
Jakovljevic, M., Malmose-Stapelfeldt, C., Milovanovic, O., Rancic, N., & Bokonjic, D. (2017). Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020. Frontiers in public health, 523. https://doi.org/10.3389/fpubh.2017.00023
Jakovljevic, Mihajlo, et al. "Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020." Frontiers in public health vol. 5 (2017): 23. doi: https://doi.org/10.3389/fpubh.2017.00023
Jakovljevic M, Malmose-Stapelfeldt C, Milovanovic O, Rancic N, Bokonjic D. Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020. Front Public Health. 2017 Feb 27;5:23. doi: 10.3389/fpubh.2017.00023. eCollection 2017. PMID: 28289676; PMCID: PMC5327442.
Copy Download .nbib Format: NLM
Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.

Trends in cancer

Medler TR, Cotechini T, Coussens LM.
PMID: 26457331
Trends Cancer. 2015 Sep 01;1(1):66-75. doi: 10.1016/j.trecan.2015.07.008.

Chemotherapy and radiotherapy have been extensively used to eradicate cancer based on their direct cytocidal effects on rapidly proliferating tumor cells. Accumulating evidence indicates that these therapies also dramatically affect resident and recruited immune cells that actively support tumor...

Cite
Medler TR, Cotechini T, Coussens LM. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer. 2015;1(1):66-75doi: 10.1016/j.trecan.2015.07.008.
Medler, T. R., Cotechini, T., & Coussens, L. M. (2015). Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends in cancer, 1(1), 66-75. https://doi.org/10.1016/j.trecan.2015.07.008
Medler, Terry R, et al. "Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance." Trends in cancer vol. 1,1 (2015): 66-75. doi: https://doi.org/10.1016/j.trecan.2015.07.008
Medler TR, Cotechini T, Coussens LM. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer. 2015 Sep 01;1(1):66-75. doi: 10.1016/j.trecan.2015.07.008. PMID: 26457331; PMCID: PMC4594836.
Copy Download .nbib Format: NLM
Glioblastoma: Defining Tumor Niches.

Trends in cancer

Hambardzumyan D, Bergers G.
PMID: 27088132
Trends Cancer. 2015 Dec;1(4):252-265. doi: 10.1016/j.trecan.2015.10.009.

Glioblastomas (GBM) are one of the most recalcitrant brain tumors because of their aggressive invasive growth and resistance to therapy. They are highly heterogeneous malignancies at both the molecular and histological levels. Specific histological hallmarks including pseudopalisading necrosis and...

Cite
Hambardzumyan D, Bergers G. Glioblastoma: Defining Tumor Niches. Trends Cancer. 2015;1(4):252-265doi: 10.1016/j.trecan.2015.10.009.
Hambardzumyan, D., & Bergers, G. (2015). Glioblastoma: Defining Tumor Niches. Trends in cancer, 1(4), 252-265. https://doi.org/10.1016/j.trecan.2015.10.009
Hambardzumyan, Dolores, and Bergers, Gabriele. "Glioblastoma: Defining Tumor Niches." Trends in cancer vol. 1,4 (2015): 252-265. doi: https://doi.org/10.1016/j.trecan.2015.10.009
Hambardzumyan D, Bergers G. Glioblastoma: Defining Tumor Niches. Trends Cancer. 2015 Dec;1(4):252-265. doi: 10.1016/j.trecan.2015.10.009. PMID: 27088132; PMCID: PMC4831073.
Copy Download .nbib Format: NLM
Why does infection with some helminths cause cancer?.

Trends in cancer

Brindley PJ, da Costa JM, Sripa B.
PMID: 26618199
Trends Cancer. 2015 Nov 01;1(3):174-182. doi: 10.1016/j.trecan.2015.08.011.

Infections with

Cite
Brindley PJ, da Costa JM, Sripa B. Why does infection with some helminths cause cancer?. Trends Cancer. 2015;1(3):174-182doi: 10.1016/j.trecan.2015.08.011.
Brindley, P. J., da Costa, J. M., & Sripa, B. (2015). Why does infection with some helminths cause cancer?. Trends in cancer, 1(3), 174-182. https://doi.org/10.1016/j.trecan.2015.08.011
Brindley, Paul J, et al. "Why does infection with some helminths cause cancer?." Trends in cancer vol. 1,3 (2015): 174-182. doi: https://doi.org/10.1016/j.trecan.2015.08.011
Brindley PJ, da Costa JM, Sripa B. Why does infection with some helminths cause cancer?. Trends Cancer. 2015 Nov 01;1(3):174-182. doi: 10.1016/j.trecan.2015.08.011. PMID: 26618199; PMCID: PMC4657143.
Copy Download .nbib Format: NLM
Targeting Transcription Factors in Cancer.

Trends in cancer

Bhagwat AS, Vakoc CR.
PMID: 26645049
Trends Cancer. 2015 Sep 01;1(1):53-65. doi: 10.1016/j.trecan.2015.07.001.

Transcription factors (TFs) are commonly deregulated in the pathogenesis of human cancer and are a major class of cancer cell dependencies. Consequently, targeting of TFs can be highly effective in treating particular malignancies, as highlighted by the clinical efficacy...

Cite
Bhagwat AS, Vakoc CR. Targeting Transcription Factors in Cancer. Trends Cancer. 2015;1(1):53-65doi: 10.1016/j.trecan.2015.07.001.
Bhagwat, A. S., & Vakoc, C. R. (2015). Targeting Transcription Factors in Cancer. Trends in cancer, 1(1), 53-65. https://doi.org/10.1016/j.trecan.2015.07.001
Bhagwat, Anand S, and Vakoc, Christopher R. "Targeting Transcription Factors in Cancer." Trends in cancer vol. 1,1 (2015): 53-65. doi: https://doi.org/10.1016/j.trecan.2015.07.001
Bhagwat AS, Vakoc CR. Targeting Transcription Factors in Cancer. Trends Cancer. 2015 Sep 01;1(1):53-65. doi: 10.1016/j.trecan.2015.07.001. PMID: 26645049; PMCID: PMC4669894.
Copy Download .nbib Format: NLM
ALTernative Telomere Maintenance and Cancer.

Trends in cancer

Dilley RL, Greenberg RA.
PMID: 26645051
Trends Cancer. 2015 Oct 01;1(2):145-156. doi: 10.1016/j.trecan.2015.07.007.

Activation of a telomere maintenance mechanism (TMM) is permissive for replicative immortality and a hallmark of human cancer. While most cancers rely on reactivation of telomerase, a significant fraction utilizes the recombination dependent alternative lengthening of telomeres (ALT) pathway....

Cite
Dilley RL, Greenberg RA. ALTernative Telomere Maintenance and Cancer. Trends Cancer. 2015;1(2):145-156doi: 10.1016/j.trecan.2015.07.007.
Dilley, R. L., & Greenberg, R. A. (2015). ALTernative Telomere Maintenance and Cancer. Trends in cancer, 1(2), 145-156. https://doi.org/10.1016/j.trecan.2015.07.007
Dilley, Robert L, and Greenberg, Roger A. "ALTernative Telomere Maintenance and Cancer." Trends in cancer vol. 1,2 (2015): 145-156. doi: https://doi.org/10.1016/j.trecan.2015.07.007
Dilley RL, Greenberg RA. ALTernative Telomere Maintenance and Cancer. Trends Cancer. 2015 Oct 01;1(2):145-156. doi: 10.1016/j.trecan.2015.07.007. PMID: 26645051; PMCID: PMC4669901.
Copy Download .nbib Format: NLM
Probing the Fifty Shades of EMT in Metastasis.

Trends in cancer

Li W, Kang Y.
PMID: 27042694
Trends Cancer. 2016 Feb;2(2):65-67. doi: 10.1016/j.trecan.2016.01.001.

The involvement of epithelial-to-mesenchymal transition (EMT) in metastasis has long been under debate. Recent efforts to probe the occurrence and functional significance of EMT in clinical samples and animal models have produced exciting but sometimes conflicting findings. The diversity...

Cite
Li W, Kang Y. Probing the Fifty Shades of EMT in Metastasis. Trends Cancer. 2016;2(2):65-67doi: 10.1016/j.trecan.2016.01.001.
Li, W., & Kang, Y. (2016). Probing the Fifty Shades of EMT in Metastasis. Trends in cancer, 2(2), 65-67. https://doi.org/10.1016/j.trecan.2016.01.001
Li, Wenyang, and Kang, Yibin. "Probing the Fifty Shades of EMT in Metastasis." Trends in cancer vol. 2,2 (2016): 65-67. doi: https://doi.org/10.1016/j.trecan.2016.01.001
Li W, Kang Y. Probing the Fifty Shades of EMT in Metastasis. Trends Cancer. 2016 Feb;2(2):65-67. doi: 10.1016/j.trecan.2016.01.001. PMID: 27042694; PMCID: PMC4815261.
Copy Download .nbib Format: NLM
The Impact of DNA Methylation in Hematopoietic Malignancies.

Trends in cancer

Guillamot M, Cimmino L, Aifantis I.
PMID: 27019871
Trends Cancer. 2016 Feb 01;2(2):70-83. doi: 10.1016/j.trecan.2015.12.006.

Aberrant DNA methylation is a characteristic feature of cancer including blood malignancies. Mutations in the DNA methylation regulators

Cite
Guillamot M, Cimmino L, Aifantis I. The Impact of DNA Methylation in Hematopoietic Malignancies. Trends Cancer. 2016;2(2):70-83doi: 10.1016/j.trecan.2015.12.006.
Guillamot, M., Cimmino, L., & Aifantis, I. (2016). The Impact of DNA Methylation in Hematopoietic Malignancies. Trends in cancer, 2(2), 70-83. https://doi.org/10.1016/j.trecan.2015.12.006
Guillamot, Maria, et al. "The Impact of DNA Methylation in Hematopoietic Malignancies." Trends in cancer vol. 2,2 (2016): 70-83. doi: https://doi.org/10.1016/j.trecan.2015.12.006
Guillamot M, Cimmino L, Aifantis I. The Impact of DNA Methylation in Hematopoietic Malignancies. Trends Cancer. 2016 Feb 01;2(2):70-83. doi: 10.1016/j.trecan.2015.12.006. PMID: 27019871; PMCID: PMC4806338.
Copy Download .nbib Format: NLM
Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Trends in cancer

Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Haskó G.
PMID: 27014745
Trends Cancer. 2016 Feb 01;2(2):95-109. doi: 10.1016/j.trecan.2016.01.003.

In recent years, cancer immunotherapy made significant advances due to a better understanding of the principles underlying tumor biology and immunology. In this context, CD73 is a key molecule, since via degradation of adenosine monophosphate into adenosine, endorses the...

Cite
Antonioli L, Yegutkin GG, Pacher P, et al. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer. 2016;2(2):95-109doi: 10.1016/j.trecan.2016.01.003.
Antonioli, L., Yegutkin, G. G., Pacher, P., Blandizzi, C., & Haskó, G. (2016). Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends in cancer, 2(2), 95-109. https://doi.org/10.1016/j.trecan.2016.01.003
Antonioli, Luca, et al. "Anti-CD73 in cancer immunotherapy: awakening new opportunities." Trends in cancer vol. 2,2 (2016): 95-109. doi: https://doi.org/10.1016/j.trecan.2016.01.003
Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Haskó G. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer. 2016 Feb 01;2(2):95-109. doi: 10.1016/j.trecan.2016.01.003. PMID: 27014745; PMCID: PMC4800751.
Copy Download .nbib Format: NLM
Novel mechanisms of regulation of miRNAs in CLL.

Trends in cancer

Balatti V, Acunzo M, Pekarky Y, Croce CM.
PMID: 27213184
Trends Cancer. 2016 Mar;2(3):134-143. doi: 10.1016/j.trecan.2016.02.005.

B-cell chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. Although, the molecular alterations leading to CLL onset and progression are still under investigation (specifically, the interplay and exact role of oncogenes and tumor suppressors in CLL...

Cite
Balatti V, Acunzo M, Pekarky Y, et al. Novel mechanisms of regulation of miRNAs in CLL. Trends Cancer. 2016;2(3):134-143doi: 10.1016/j.trecan.2016.02.005.
Balatti, V., Acunzo, M., Pekarky, Y., & Croce, C. M. (2016). Novel mechanisms of regulation of miRNAs in CLL. Trends in cancer, 2(3), 134-143. https://doi.org/10.1016/j.trecan.2016.02.005
Balatti, Veronica, et al. "Novel mechanisms of regulation of miRNAs in CLL." Trends in cancer vol. 2,3 (2016): 134-143. doi: https://doi.org/10.1016/j.trecan.2016.02.005
Balatti V, Acunzo M, Pekarky Y, Croce CM. Novel mechanisms of regulation of miRNAs in CLL. Trends Cancer. 2016 Mar;2(3):134-143. doi: 10.1016/j.trecan.2016.02.005. PMID: 27213184; PMCID: PMC4874335.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 235 entries